Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: J Psychopharmacol. 2016 Sep 27;31(1):17–30. doi: 10.1177/0269881116668590

Table 4.

Mean BOLD activation to outcome trials, by group.

METH− METH+
ROI Hemisphere Gain Loss Gain Loss
Ventral Striatum Left −0.05 ± 0.98 −0.17 ± 0.74 0.26 ± 1.23 −0.24 ± 0.89
Right 0.08 ± 1.55 0.28 ± 1.05 0.25 ± 1.24 −0.21 ± 0.89
Anterior Caudate* Left −0.05 ± 0.71 0.08 ± 0.76 0.09 ± 1.05 −0.46 ± 1.02
Right −0.29 ± 1.29 −0.01 ± 0.80 0.26 ± 0.84 −0.22 ± 0.78
Posterior Caudate* Left −0.09 ± 0.73 0.15 ± 0.80 0.23 ± 0.90 −0.35 ± 0.95
Right −0.28 ± 0.70 0.09 ± 0.80 0.30 ± 0.89 −0.08 ± 0.59

Note: BOLD activation reported as mean ± SD. METH−: healthy comparison participants; METH+: participants with a history of methamphetamine dependence. Significant statistical values are reported in main text;

*

Significant group x outcome interaction.